Approximately 10% of thyroid nodules are autonomous functioning thyroid nodules (AFTNs), making it the third most common cause of hyperthyroidism after Graves’ disease and toxic multinodular goiter. In the management of benign thyroid nodules, there is a current trend toward minimizing surgical risks by utilizing minimally invasive techniques like ultrasound-guided radiofrequency ablation (RFA-US). Another treatment option for these cases is radioactive iodine (RAI), but it is not without risks. As a result, RFA-US has emerged as a new technology that offers the advantages of volume rate reduction (VRR) and biochemical control while avoiding the potential risks associated with surgery and RAI. This chapter will present the evidence supporting the use of RFA-US in AFTNs.